基本信息
views: 235
Career Trajectory
Bio
I founded our Developmental Therapeutics (Phase I trials) Working Group at UNC-LCCC, and now direct the early phase clinical trials program, and the breast cancer clinical trials group. I co-lead the LCCC Clinical Research Program. My research focuses on early phase clinical trials of novel therapeutics, especially those focused on breast cancer. I have been the principal investigator for over 100 trials including 10 currently open early phase trials. I am the PI at UNC for the current Duke-UNC-Wash U Partnership in the ETCTN (UM1 grant), as well as a co-investigator on our NCTN grant and site PI for NRG. I have authored or co-authored over 85 papers. I am a member of the CALGB (ALLIANCE) pharmacogenomics and pharmacology committee, and have been a member of ASCO program committees, ABIM Medical Oncology Board Certification committee, peer review panels for DOD, Komen, and NIH, and also an ad hoc reviewer for a number of journals. I have co-mentored a number of fellows in oncology and pharmacology.
Research Interests
Papers共 298 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
LANCET ONCOLOGYno. 4 (2024): 474-487
JAMA oncologyno. 2 (2024): 193-201
Cancer Researchno. 6_Supplement (2024): 6427-6427
Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Journal of Clinical Oncologyno. 16_suppl (2024): 1015-1015
Cancer Researchno. 9_Supplement (2024): PO4-10
Cancer Researchno. 9_Supplement (2024): RF02-06
CANCER RESEARCHno. 8 (2023)
CANCER RESEARCHno. 5 (2023)
Cancer Researchno. 8_Supplement (2023): CT145-CT145
Load More
Author Statistics
#Papers: 0
#Citation: 0
H-Index: 0
G-Index: 0
Sociability: 0
Diversity: 0
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn